The Vadodara based pharmaceutical company Alembic Pharmaceuticals reported a 31 per cent increase in net sales to Rs 486.74 crores for the quarter ended 31st December 2013, compared to Rs 372.05 crores in the corresponding quarter last year.
The company registered 48 per cent growth in profit before tax at Rs 88.83 crores for the quarter ended 31st December 2013 against Rs 60.09 crores in corresponding quarter of last fiscal. Its net profit grew by 37 per cent at Rs 65.93 crores for the quarter ended 31st December 2013 against Rs 48.27 crores in corresponding quarter last fiscal.
Its EBIDTA margins for quarter ended 31st December 13 up at 21 per cent to Rs 102.23 crores from 18.64 per cent at Rs 69.36 crores for corresponding quarter last year.
The company also reported 22 per cent increase in revenue for YTD Dec 13 to Rs 1403.19 crores against Rs 1147.64 crores for corresponding period last year. The company also posted 52 per cent growth in profit before tax at Rs. 229.82 crores for YTD Dec 13 against Rs151.17 crores for corresponding period last year. The company also reported 43 per cent growth in net profit for YTD Dec 13 at Rs 174.21 crores against Rs 121.60 crores in corresponding period last year.
The company’s domestic branded formulations business posted sales of Rs 229.57 crores against Rs 199.85 crores with a 15 per cent growth over the corresponding quarter of the previous year.
As per ORG IMS, Alembic has market share of 1.76 per cent (MAT-Nov 13). Gestofit has featured as company’s 5th brand in top 300 brands list of IMS-ORG. Specialty and Acute segments grew by 22 per cent and -two per cent respectively in current years (MAT-Nov 13) versus Industry growth rate of 11 per cent and two per cent respectively.
Alembic Pharma’s international generic formulation achieved growth of 112 per cent and posted sales of Rs 129.62 crores against Rs 61.05 crores over the corresponding quarter last year. During the quarter one ANDA application were filed taking cumulative ANDA filings of the company to 60. One ANDA approval was received during the quarter. The company’s cumulative ANDA approvals now stand at 31 (including four tentative approvals). During the quarter two DMF applications were filed taking cumulative DMF filings of the company to 64.
EP News Bureau– Mumbai